NL-OMON51579已完成不适用
A Study to Evaluate the Safety, Tolerability, and Effects on NSAID-Induced Small Bowel Pathology of K-196 in Healthy Volunteers. - CS0394
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64(—)
入选标准
- •1. Understand the trial procedures and agree to participate by providing
- •written informed consent.
- •2. Be willing and able to comply with all trial procedures and restrictions.
- •3. Be healthy between 18 to 59 years of age, inclusive, at the Screening Visit.
- •4. Have a Body Mass Index (BMI) >=18.0 and <30.0 (kg/m2) at the Screening Visit.
- •5. Be a nonsmoker who has not used tobacco or nicotine-containing products
- •(e.g., nicotine patch) for at least 3 months before administration of the
- •initial dose of trial drug and agrees to abstain from smoking tobacco or the
- •use of nicotine-containing products while on study.
- •6. Be judged to be in good health by the Investigator, based on clinical
- •evaluations including laboratory safety tests, medical history, physical
- •examination, 12-lead ECG, and vital sign measurements performed at the
- •Screening Visit and before administration of the initial dose of trial drug.
排除标准
- •1. Has participated in another investigational study within the following time
- •period: 30 days, 5 half-lives or twice the duration of the biological effect of
- •the investigational product (whichever is longer or based on local regulations)
- •prior to the Screening Visit. The window will be derived from the date of the
- •last study procedure and/or AE related to the study procedure in the previous
- •study to the Screening Visit of the current study.
- •2. Is an employee or immediate family member (e.g., spouse, parent, child,
- •sibling) of the Sponsor or study site.
- •3. Has a history of significant multiple and/or severe allergies (e.g., food,
- •drug, latex allergy) or has had an anaphylactic reaction or significant
- •intolerance to prescription or nonprescription drugs or food.
- •4. Has a known hypersensitivity or contraindication to any component of K-196,
- •related compounds or its excipients.
- •5. Has known hypersensitivity to naproxen or any components of the drug product
- •6. Has history of asthma, urticaria or other allergic-type reactions after
- •taking naproxen or other NSAIDs.
研究者
相似试验
进行中(未招募)
1 期
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaMaintenance treatment of schizophrenia in patients currently treated with oral antipsychoticsMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2019-000063-24-FRTeva Branded Pharmaceutical Products R&D, Inc.300
进行中(未招募)
1 期
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaEUCTR2019-000063-24-BGTeva Branded Pharmaceutical Products R&D, Inc.340
尚未招募
1 期
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part AChronic Myeloid Leukaemia (CML)Parkinson's Disease (PD)Cancer - Leukaemia - Chronic leukaemiaNeurological - Parkinson's diseaseACTRN12624000115538Enliven Therapeutics, Inc.15
尚未招募
1 期
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part BChronic Myeloid Leukaemia (CML)Parkinson's Disease (PD)Cancer - Leukaemia - Chronic leukaemiaNeurological - Parkinson's diseaseACTRN12624000116527Enliven Therapeutics, Inc.15
已完成
2 期
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy VolunteersA (Healthy Volunteers)Healthy CoronavirusY59.9LBCTR2020113522Inovio Pharmaceuticals, Inc.542
